Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2025)
Roivant Sciences (ROIV) posted Income from Continuing Operations of 753651000.0 for Q4 2025, down 353.9% on a QoQ basis from 166039000.0 in Q3 2025, and down 66.38% year-over-year from 2241716427.54 in Q4 2024.
Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Roivant Sciences' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 753651000.0 for Q4 2025.
- Quarterly Income from Continuing Operations fell 66.38% year-over-year to 753651000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1646569000.0 (down 137.38% YoY) and the FY2026 annual result came in at 397907000.0, up 45.47% from the prior year.
- Income from Continuing Operations was 753651000.0 for Q4 2025 at Roivant Sciences, down from 166039000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5126269000.0 in Q4 2023 and bottomed at 1054601000.0 in Q4 2022.
- A 5-year average of 3003866.67 and a median of 273911000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations slumped 1167.12% — and 2023, when it soared 586.09%.
- Roivant Sciences' Income from Continuing Operations stood at 632803000.0 in 2021, then sank by 66.66% to 1054601000.0 in 2022, then surged by 586.09% to 5126269000.0 in 2023, then slumped by 108.84% to 452968000.0 in 2024, then tumbled by 66.38% to 753651000.0 in 2025.
- Business Quant data shows ROIV's Income from Continuing Operations at 753651000.0 in Q4 2025, 166039000.0 in Q3 2025, and 273911000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -753.65 Mn |
| Sep 30, 2025 | -166.04 Mn |
| Jun 30, 2025 | -273.91 Mn |
| Dec 31, 2024 | -452.97 Mn |
| Sep 30, 2024 | -236.84 Mn |
| Jun 30, 2024 | -31.60 Mn |
| Dec 31, 2023 | 5.13 Bn |
| Sep 30, 2023 | -244.64 Mn |
| Jun 30, 2023 | -327.85 Mn |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -315.92 Mn |
| Jun 30, 2022 | -353.78 Mn |
| Dec 31, 2021 | -632.80 Mn |
| Sep 30, 2021 | -225.64 Mn |
| Jun 30, 2021 | -101.08 Mn |
| Dec 31, 2020 | -275.60 Mn |
| Sep 30, 2020 | -53.50 Mn |
| Jun 30, 2020 | -7.98 Mn |